Article | Published:

Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism

Nature Chemical Biology volume 9, pages 97104 (2013) | Download Citation

Abstract

Improving the control of energy homeostasis can lower cardiovascular risk in metabolically compromised individuals. To identify new regulators of whole-body energy control, we conducted a high-throughput screen in transgenic reporter zebrafish for small molecules that modulate the expression of the fasting-inducible gluconeogenic gene pck1. We show that this in vivo strategy identified several drugs that affect gluconeogenesis in humans as well as metabolically uncharacterized compounds. Most notably, we find that the translocator protein ligands PK 11195 and Ro5-4864 are glucose-lowering agents despite a strong inductive effect on pck1 expression. We show that these drugs are activators of a fasting-like energy state and, notably, that they protect high-fat diet–induced obese mice from hepatosteatosis and glucose intolerance, two pathological manifestations of metabolic dysregulation. Thus, using a whole-organism screening strategy, this study has identified new small-molecule activators of fasting metabolism.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Deaths from coronary heart disease. in The Atlas of Heart Disease and Stroke. 48–49 (World Health Organization, 2008).

  2. 2.

    & Obesity. Lancet 366, 1197–1209 (2005).

  3. 3.

    & Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9, 193–205 (2008).

  4. 4.

    Insulin resistance. Prosperity's plague. Science 325, 256–260 (2009).

  5. 5.

    et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337–342 (2006).

  6. 6.

    , & Cellular bioenergetics as a target for obesity therapy. Nat. Rev. Drug Discov. 9, 465–482 (2010).

  7. 7.

    Driving drug discovery: the fundamental role of academic labs. Sci. Transl. Med. 2, 30cm16 (2010).

  8. 8.

    & How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507–519 (2011).

  9. 9.

    & In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4, 35–44 (2005).

  10. 10.

    & Lessons from 'lower' organisms: what worms, flies, and zebrafish can teach us about human energy metabolism. PLoS Genet. 3, e199 (2007).

  11. 11.

    , , , & Aspects of the control of phosphoenolpyruvate carboxykinase gene transcription. J. Biol. Chem. 284, 27031–27035 (2009).

  12. 12.

    & Hormonal regulation of hepatic glucose production in health and disease. Cell Metab. 14, 9–19 (2011).

  13. 13.

    et al. Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab. 5, 313–320 (2007).

  14. 14.

    et al. Suppression of lens growth by αA-crystallin promoter-driven expression of diphtheria toxin results in disruption of retinal cell organization in zebrafish. Dev. Biol. 255, 113–127 (2003).

  15. 15.

    et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456, 269–273 (2008).

  16. 16.

    Current concepts of gluconeogenesis. Am. J. Clin. Nutr. 20, 282–289 (1967).

  17. 17.

    et al. Mice with a deletion in the gene for CCAAT/enhancer-binding protein β have an attenuated response to cAMP and impaired carbohydrate metabolism. J. Biol. Chem. 276, 629–638 (2001).

  18. 18.

    et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120, 2355–2369 (2010).

  19. 19.

    et al. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene 24, 7503–7513 (2005).

  20. 20.

    et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discov. 9, 971–988 (2010).

  21. 21.

    , , , & Characterization of ligand binding to mitochondrial benzodiazepine receptors. Mol. Pharmacol. 35, 164–172 (1989).

  22. 22.

    , , & Characterization of peripheral-type benzodiazepine binding sites in brain using [3H]Ro 5–4864. Mol. Pharmacol. 22, 26–32 (1982).

  23. 23.

    , , & Comparative analysis of gene regulation by the transcription factor PPARα between mouse and human. PLoS ONE 4, e6796 (2009).

  24. 24.

    et al. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489–1498 (1999).

  25. 25.

    et al. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc. Natl. Acad. Sci. USA 100, 6216–6220 (2003).

  26. 26.

    et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325, 490–493 (2009).

  27. 27.

    , & Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 9, 447–464 (2010).

  28. 28.

    , & Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc. Natl. Acad. Sci. USA 84, 2256–2260 (1987).

  29. 29.

    et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27, 402–409 (2006).

  30. 30.

    & Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc. Natl. Acad. Sci. USA 74, 3805–3809 (1977).

  31. 31.

    et al. CRTC3 links catecholamine signalling to energy balance. Nature 468, 933–939 (2010).

  32. 32.

    et al. Glucose metabolism and catecholamines. Crit. Care Med. 35, S508–S518 (2007).

  33. 33.

    et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 55, 650–656 (2000).

  34. 34.

    et al. LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J. Clin. Invest. 121, 431–441 (2011).

  35. 35.

    & Glucocorticoids, metabolism and metabolic diseases. Mol. Cell. Endocrinol. 275, 43–61 (2007).

  36. 36.

    et al. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology 85, 61–70 (2007).

  37. 37.

    , , , & Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 51, 2309–2317 (2008).

  38. 38.

    Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (suppl. 1), 1–93 (2005).

  39. 39.

    , & Inhibition of insulin release from the rat pancreas by cyproheptadine and tricyclic antidepressants. Naunyn Schmiedebergs Arch. Pharmacol. 285, 99–102 (1974).

  40. 40.

    , , & Modulation of glucose homeostasis by doxepin. Methods Find. Exp. Clin. Pharmacol. 14, 61–71 (1992).

  41. 41.

    et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia 55, 63–72 (2012).

  42. 42.

    et al. Serotonin regulates C. elegans fat and feeding through independent molecular mechanisms. Cell Metab. 7, 533–544 (2008).

  43. 43.

    et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS ONE 6, e21551 (2011).

  44. 44.

    , , & Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am. J. Psychiatry 166, 591–598 (2009).

  45. 45.

    et al. I-SceI meganuclease mediates highly efficient transgenesis in fish. Mech. Dev. 118, 91–98 (2002).

  46. 46.

    et al. Dynamic glucoregulation and mammalian-like responses to metabolic and developmental disruption in zebrafish. Gen. Comp. Endocrinol. 170, 334–345 (2011).

  47. 47.

    , & 435-bpliver regulatory sequence in the liver fatty acid binding protein (L-FABP) gene is sufficient to modulate liver regional expression in transgenic zebrafish. Dev. Dyn. 227, 347–356 (2003).

  48. 48.

    & KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).

  49. 49.

    et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway. Cell Metab. 4, 199–210 (2006).

  50. 50.

    et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol. Cell 44, 177–190 (2011).

  51. 51.

    & High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat. Protoc. 3, 59–69 (2008).

Download references

Acknowledgements

The authors thank A. Schlegel, O. Stone and K. Ashrafi for critical reading of the manuscript; the members of the Stainier lab for technical advice throughout the project; and A. Ayala, M. Alva, P. Lopez Pazmino and M. Sklar for zebrafish care. We are grateful to C. Miller from the Gladstone Histology Core for histological processing of mouse livers. We also thank R. Peterson for sharing knowledge on in vivo bioluminescence measurements in zebrafish. This study was supported in part by a postdoctoral fellowship DFG GU 1082/101 from the German Research Foundation to P.G., grant DK59637 to the Mouse Metabolic Phenotypic Centers lipid lab, Pilot/Feasibility grants from the University of California–San Francisco Liver Center (P30 DK026743) and Diabetes and Endocrinology Center (P30 DK063720), US National Institutes of Health (NIH) grant NS051470 to K.A., funds from the Gladstone Institutes and the Glenn Foundation for Medical Research to E.V., the American Heart Association grant 12SDG8840004 to M.D.H., NIH grant RO1 DK60322, a pilot and feasibility award from the University of California–San Fransisco diabetes center funded by NIH U01 DK089541 and the Packard Foundation to D.Y.R.S.

Author information

Author notes

    • Olov Andersson
    • , Daniel Hesselson
    •  & Didier Y R Stainier

    Present addresses: Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (O.A.); Garvan Institute of Medical Research, Diabetes and Obesity Research Program, Darlinghurst, New South Wales, Australia (D.H.); Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (D.Y.R.S.).

Affiliations

  1. Department of Biochemistry and Biophysics, University of California–San Francisco, San Francisco, California, USA.

    • Philipp Gut
    • , Olov Andersson
    • , Laura Hasenkamp
    • , Joseph Hsiao
    • , Daniel Hesselson
    •  & Didier Y R Stainier
  2. Program in Developmental and Stem Cell Biology, University of California–San Francisco, San Francisco, California, USA.

    • Philipp Gut
    • , Olov Andersson
    • , Laura Hasenkamp
    • , Joseph Hsiao
    • , Daniel Hesselson
    •  & Didier Y R Stainier
  3. Program in Genetics and Human Genetics, University of California–San Francisco, San Francisco, California, USA.

    • Philipp Gut
    • , Olov Andersson
    • , Laura Hasenkamp
    • , Joseph Hsiao
    • , Daniel Hesselson
    •  & Didier Y R Stainier
  4. The Diabetes Center, University of California–San Francisco, San Francisco, California, USA.

    • Philipp Gut
    • , Olov Andersson
    • , Laura Hasenkamp
    • , Joseph Hsiao
    • , Daniel Hesselson
    •  & Didier Y R Stainier
  5. Institute for Regeneration Medicine and Liver Center, University of California–San Francisco, San Francisco, California, USA.

    • Philipp Gut
    • , Olov Andersson
    • , Laura Hasenkamp
    • , Joseph Hsiao
    • , Daniel Hesselson
    •  & Didier Y R Stainier
  6. The Gladstone Institute of Neurological Disease, San Francisco, California, USA.

    • Bernat Baeza-Raja
    •  & Katerina Akassoglou
  7. The Gladstone Institute of Virology and Immunology, San Francisco, California, USA.

    • Eric Verdin
    •  & Matthew D Hirschey
  8. Department of Medicine, University of California–San Francisco, San Francisco, California, USA.

    • Eric Verdin
    •  & Matthew D Hirschey
  9. Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, North Carolina, USA.

    • Matthew D Hirschey
  10. Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

    • Matthew D Hirschey
  11. Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.

    • Matthew D Hirschey

Authors

  1. Search for Philipp Gut in:

  2. Search for Bernat Baeza-Raja in:

  3. Search for Olov Andersson in:

  4. Search for Laura Hasenkamp in:

  5. Search for Joseph Hsiao in:

  6. Search for Daniel Hesselson in:

  7. Search for Katerina Akassoglou in:

  8. Search for Eric Verdin in:

  9. Search for Matthew D Hirschey in:

  10. Search for Didier Y R Stainier in:

Contributions

P.G. conceived the study, designed and performed experiments, analyzed data and wrote the paper. D.Y.R.S. designed experiments, analyzed data, supervised the work and wrote the paper. M.D.H. designed and performed experiments and analyzed data. O.A., B.B.-R., D.H., L.H. and J.H. performed experiments. K.A. and E.V. contributed material and supervised the work. All authors commented on the paper.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Philipp Gut or Didier Y R Stainier.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Results

Excel files

  1. 1.

    Supplementary Table 3

    Supplementary Table 3

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nchembio.1136

Further reading